Invidious Price Discrimination in the Sale of Rapid Acting Insulin: Is There An Antitrust Remedy?
By Warren S. Grimes (Southwestern Law School)
Price discrimination is rampant in the sale of rapid acting insulin and other patented drugs. That discrimination frequently results in uninsured or under-insured patients paying the highest prices. I focus here primarily on the possibility that the targeted discrimination could constitute abusive conduct by a dominant firm. My conclusion is that, while price discrimination is not the primary cause of high insulin prices, it is key to an abusive scheme that reduces output, raises prices for vulnerable patients, and constitutes a clear consumer welfare injury. This coercive conduct should give rise to valid claims for monopolization or attempted monopolization, for related claims under the Robinson Patman Act, or for a separate violation of Section 5 of the FTC Act. The broader implications for antitrust policy are that discrimination that targets disadvantaged groups is common in the marketing of patented drugs and can also occur in the marketing of other products, such as strongly branded, trademarked products.
Featured News
Judge Mehta Questions Both Sides in Landmark Google Antitrust Case
May 2, 2024 by
CPI
FCC Urges Urgent Funding for Removal of Chinese Telecom Equipment from U.S. Networks
May 2, 2024 by
CPI
Former Pioneer CEO Facing Potential Criminal Charges For Colluding With OPEC
May 2, 2024 by
CPI
South Korea’s Antitrust Regulator Greenlights K-Pop Powerhouse Deal
May 2, 2024 by
CPI
Exxon’s Pioneer Purchase Approved, Former CEO Barred from Board
May 2, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI